{"id":7571,"date":"2007-10-08T18:44:00","date_gmt":"2007-10-08T18:44:00","guid":{"rendered":"http:\/\/www.pharma-mkting.com\/rozerem-wall-street-analysts-miss-you\/"},"modified":"2019-02-21T01:25:35","modified_gmt":"2019-02-21T01:25:35","slug":"rozerem-wall-street-analysts-miss-you","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/rozerem-wall-street-analysts-miss-you\/","title":{"rendered":"Rozerem: Wall Street Analysts Miss You!"},"content":{"rendered":"<p><a onblur=\"try {parent.deselectBloggerImageGracefully();} catch(e) {}\" href=\"http:\/\/bp0.blogger.com\/_ZiPiXEv_Q_g\/RwqAVSZvXUI\/AAAAAAAAAyc\/ihRWvf9np90\/s1600-h\/Rozeremboycott.jpg\"><img decoding=\"async\" style=\"margin: 0pt 10px 10px 0pt; float: left; cursor: pointer;\" src=\"http:\/\/bp0.blogger.com\/_ZiPiXEv_Q_g\/RwqAVSZvXUI\/AAAAAAAAAyc\/ihRWvf9np90\/s200\/Rozeremboycott.jpg\" alt=\"\" id=\"BLOGGER_PHOTO_ID_5119045029665398082\" border=\"0\" \/><\/a><br \/>Rozerem is not on equity analysts&#8217; radar screens!<\/p>\n<p>That&#8217;s my conclusion after reading the BusinessWeek article &#8220;<a href=\"http:\/\/www.businessweek.com\/investor\/content\/oct2007\/pi2007105_564105.htm\">Sleep Drugs Rouse Big Pharma<\/a>,&#8221; which talks about current and future insomnia medications. The article summarized an &#8220;Insight&#8221; report written by Steven Silver and Herman Saftlas, both equity analysts for Standard &amp; Poor&#8217;s.<\/p>\n<p>The analysts mentioned Ambien, Ambrien CR, and Lunesta in their analysis plus several generics (temazepam and zolpidem). But nowhere in the story was there mention of Rozerem!<\/p>\n<p>My interpretation: Rozerem&#8217;s market share is too insignificant for it to be included in a serious analysis of the insomnia market!<\/p>\n<p>This is even more surprising because the analysts claim only 10% &#8211; 15% of insomnia sufferers seek treatment primarily because of side effect (ie, dependence) fears:<\/p>\n<p>&#8220;Approximately 70 million people in the U.S. suffer regular or occasional insomnia, according to Steven Silver, a biotechnology equity analyst for Standard &amp; Poor&#8217;s. But only 10% to 15% seek treatment, in part because of the side effects associated with the current crop of insomnia drugs.&#8221;<\/p>\n<p>But Rozerem ads claim that it is different (&#8220;Your doctor can explain how&#8221;) and Abe says &#8220;not to worry&#8221; about dependence!<\/p>\n<p>&#8220;Since many insomnia drugs are sold directly to consumers, sales are greatly influenced by consumer print and broadcast advertising,&#8221; says the BusinessWeek article.<\/p>\n<p>I guess the Rozerem marketing message is falling on deaf ears, or maybe people don&#8217;t believe Abe is as honest as he claims to be!<\/p>\n<p>This is yet another confirmation of my contention that &#8220;<a href=\"http:\/\/pharma-mkting.com\/blog\/2006\/10\/rozerem-ads-innovatively-ineffectual_26.html\">Rozerem Ads are Innovatively Ineffectual<\/a>.&#8221;<\/p>\n<p>Sorry, Rozerem. But don&#8217;t worry, your ads still may win awards (see <a href=\"http:\/\/pharma-mkting.com\/blog\/2007\/09\/poe-dtc-forevermore.html\">here<\/a>).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rozerem is not on equity analysts&#8217; radar screens! That&#8217;s my conclusion after reading the BusinessWeek article &#8220;Sleep Drugs Rouse Big Pharma,&#8221; which talks about current and future insomnia medications. The article summarized an &#8220;Insight&#8221; report written by Steven Silver and Herman Saftlas, both equity analysts for Standard &amp; Poor&#8217;s. The analysts mentioned Ambien, Ambrien CR, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":13101,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12],"tags":[982,1130,986,79],"topic":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Rozerem: Wall Street Analysts Miss You! - Pharma Marketing Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/rozerem-wall-street-analysts-miss-you\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rozerem: Wall Street Analysts Miss You! - Pharma Marketing Network\" \/>\n<meta property=\"og:description\" content=\"Rozerem is not on equity analysts&#8217; radar screens! That&#8217;s my conclusion after reading the BusinessWeek article &#8220;Sleep Drugs Rouse Big Pharma,&#8221; which talks about current and future insomnia medications. The article summarized an &#8220;Insight&#8221; report written by Steven Silver and Herman Saftlas, both equity analysts for Standard &amp; Poor&#8217;s. The analysts mentioned Ambien, Ambrien CR, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/rozerem-wall-street-analysts-miss-you\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Marketing Network\" \/>\n<meta property=\"article:published_time\" content=\"2007-10-08T18:44:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-02-21T01:25:35+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2019\/03\/pmn-logo-intro-post-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"744\" \/>\n\t<meta property=\"og:image:height\" content=\"419\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pharma Guy\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pharma Guy\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/rozerem-wall-street-analysts-miss-you\/\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/rozerem-wall-street-analysts-miss-you\/\",\"name\":\"Rozerem: Wall Street Analysts Miss You! - Pharma Marketing Network\",\"isPartOf\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website\"},\"datePublished\":\"2007-10-08T18:44:00+00:00\",\"dateModified\":\"2019-02-21T01:25:35+00:00\",\"author\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1\"},\"breadcrumb\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/rozerem-wall-street-analysts-miss-you\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/rozerem-wall-street-analysts-miss-you\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/rozerem-wall-street-analysts-miss-you\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rozerem: Wall Street Analysts Miss You!\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/\",\"name\":\"Pharma Marketing Network\",\"description\":\"Pharma Marketing Network\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1\",\"name\":\"Pharma Guy\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/image\/\",\"url\":\"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g\",\"contentUrl\":\"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g\",\"caption\":\"Pharma Guy\"},\"description\":\"Pharmaguy\u2122 is a \u201cconstructive critic\u201d of pharma marketing and publishes commentary on the Pharma Marketing Blog and on Scoop.it.\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/author\/ehs-pharmaguy\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rozerem: Wall Street Analysts Miss You! - Pharma Marketing Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/rozerem-wall-street-analysts-miss-you\/","og_locale":"en_US","og_type":"article","og_title":"Rozerem: Wall Street Analysts Miss You! - Pharma Marketing Network","og_description":"Rozerem is not on equity analysts&#8217; radar screens! That&#8217;s my conclusion after reading the BusinessWeek article &#8220;Sleep Drugs Rouse Big Pharma,&#8221; which talks about current and future insomnia medications. The article summarized an &#8220;Insight&#8221; report written by Steven Silver and Herman Saftlas, both equity analysts for Standard &amp; Poor&#8217;s. The analysts mentioned Ambien, Ambrien CR, [&hellip;]","og_url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/rozerem-wall-street-analysts-miss-you\/","og_site_name":"Pharma Marketing Network","article_published_time":"2007-10-08T18:44:00+00:00","article_modified_time":"2019-02-21T01:25:35+00:00","og_image":[{"width":744,"height":419,"url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2019\/03\/pmn-logo-intro-post-1.jpg","type":"image\/jpeg"}],"author":"Pharma Guy","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pharma Guy","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/rozerem-wall-street-analysts-miss-you\/","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/rozerem-wall-street-analysts-miss-you\/","name":"Rozerem: Wall Street Analysts Miss You! - Pharma Marketing Network","isPartOf":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website"},"datePublished":"2007-10-08T18:44:00+00:00","dateModified":"2019-02-21T01:25:35+00:00","author":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1"},"breadcrumb":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/rozerem-wall-street-analysts-miss-you\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/rozerem-wall-street-analysts-miss-you\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/rozerem-wall-street-analysts-miss-you\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/"},{"@type":"ListItem","position":2,"name":"Rozerem: Wall Street Analysts Miss You!"}]},{"@type":"WebSite","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/","name":"Pharma Marketing Network","description":"Pharma Marketing Network","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1","name":"Pharma Guy","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/image\/","url":"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g","contentUrl":"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g","caption":"Pharma Guy"},"description":"Pharmaguy\u2122 is a \u201cconstructive critic\u201d of pharma marketing and publishes commentary on the Pharma Marketing Blog and on Scoop.it.","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/author\/ehs-pharmaguy\/"}]}},"_links":{"self":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/7571"}],"collection":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/comments?post=7571"}],"version-history":[{"count":1,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/7571\/revisions"}],"predecessor-version":[{"id":8656,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/7571\/revisions\/8656"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/media\/13101"}],"wp:attachment":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/media?parent=7571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/categories?post=7571"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/tags?post=7571"},{"taxonomy":"topic","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/topic?post=7571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}